{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:05:31Z","timestamp":1785168331724,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma is an incurable hematologic malignancy. Although novel treatments have improved outcomes, many patients continue to relapse and eventually develop treatment resistance. Elranatamab, a bispecific antibody, has demonstrated promising efficacy in patients with relapsed\/refractory multiple myeloma. However, clinical experience with elranatamab remains limited, and its immunomodulatory effects may increase the risk of opportunistic infections and viral reactivation. Here, we describe hepatitis B virus (HBV) reactivation in a patient with resolved HBV infection who was treated with elranatamab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 76-year-old man with resolved HBV infection and treatment-resistant multiple myeloma received elranatamab. HBV DNA was not detected prior to treatment. On day 17 after initiation, an outpatient specimen returned as detectable but below the assay\u2019s lower limit of quantification (&lt;\u20091.0 log10 IU\/mL). Elranatamab was discontinued due to hypotension, and the patient was subsequently hospitalized one week later with pneumonia. On day 78 after initiation, HBV DNA increased to 3.6 log10 IU\/mL with transaminase elevation; tenofovir alafenamide 25\u00a0mg once daily was started the same day, after which HBV DNA declined to below the lower limit of quantification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although elranatamab-specific information on HBV reactivation is limited, this case highlights a clinically relevant risk. Clinicians should remain vigilant for reactivation in patients receiving elranatamab, particularly those with resolved infection. Regular HBV DNA monitoring and prompt initiation of nucleos(t)ide analog therapy are essential to prevent severe complications, including fulminant hepatitis. Additionally, in the context of profound hypogammaglobulinemia during or after elranatamab, intravenous immunoglobulin may be considered to mitigate infection risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-025-00506-6","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T14:14:53Z","timestamp":1761228893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A case of hepatitis B virus reactivation after elranatamab therapy in a patient with multiple myeloma"],"prefix":"10.1186","volume":"11","author":[{"given":"Naoaki","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yoshikuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"5","key":"506_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548\u201367. https:\/\/doi.org\/10.1002\/ajh.25791.","journal-title":"Am J Hematol"},{"issue":"9","key":"506_CR2","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266\u201375. https:\/\/doi.org\/10.1038\/s41375-019-0435-7.","journal-title":"Leukemia"},{"issue":"4","key":"506_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005. https:\/\/doi.org\/10.1038\/s41375-020-0734-z.","journal-title":"Leukemia"},{"issue":"1","key":"506_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13(1):125. https:\/\/doi.org\/10.1186\/s13045-020-00962-7.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"506_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","volume":"31","author":"A Seckinger","year":"2017","unstructured":"Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, et al. Target Expression, Generation, preclinical Activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31(3):396\u2013410. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.002.","journal-title":"Cancer Cell"},{"issue":"9","key":"506_CR6","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Prince HM, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259\u201367. https:\/\/doi.org\/10.1038\/s41591-023-02528-9.","journal-title":"Nat Med"},{"issue":"1","key":"506_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023;13(1):116. https:\/\/doi.org\/10.1038\/s41408-023-00879-7.","journal-title":"Blood Cancer J"},{"issue":"8","key":"506_CR8","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1080\/10428190500472503","volume":"47","author":"P Sch\u00fctt","year":"2006","unstructured":"Sch\u00fctt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, M\u00fcller S, et al. Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leuk Lymphoma. 2006;47(8):1570\u201382. https:\/\/doi.org\/10.1080\/10428190500472503.","journal-title":"Leuk Lymphoma"},{"key":"506_CR9","doi-asserted-by":"publisher","first-page":"1078725","DOI":"10.3389\/fonc.2023.1078725","volume":"13","author":"L John","year":"2023","unstructured":"John L, Miah K, Benner A, Mai EK, Kriegsmann K, Hundemer M, et al. Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed\/refractory multiple myeloma. Front Oncol. 2023;13:1078725. https:\/\/doi.org\/10.3389\/fonc.2023.1078725.","journal-title":"Front Oncol"},{"issue":"5","key":"506_CR10","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/CCO.0000000000000869","volume":"34","author":"PA Baeuerle","year":"2022","unstructured":"Baeuerle PA, Wesche H. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. Curr Opin Oncol. 2022;34(5):552\u20138. https:\/\/doi.org\/10.1097\/CCO.0000000000000869.","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"506_CR11","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European myeloma network. Lancet Oncol. 2023;24(6):e255\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(23)00159-6.","journal-title":"Lancet Oncol"},{"issue":"8","key":"506_CR12","doi-asserted-by":"publisher","first-page":"e7048","DOI":"10.1002\/cam4.7048","volume":"13","author":"K Uttervall","year":"2024","unstructured":"Uttervall K, T\u00e4tting L, Lemonakis K, Majd M, Crafoord J, Olsson M, et al. Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden. Cancer Med. 2024;13(8):e7048. https:\/\/doi.org\/10.1002\/cam4.7048.","journal-title":"Cancer Med"},{"issue":"1","key":"506_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41408-024-01107-6","volume":"14","author":"A Wonnaparhown","year":"2024","unstructured":"Wonnaparhown A, Hilal T, Squire J, Freeman C, Fonseca R. IgG replacement in multiple myeloma. Blood Cancer J. 2024;14(1):124. https:\/\/doi.org\/10.1038\/s41408-024-01107-6.","journal-title":"Blood Cancer J"},{"issue":"9","key":"506_CR14","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.3390\/jcm9093022","volume":"9","author":"B Dalla Palma","year":"2020","unstructured":"Dalla Palma B, Marchica V, Catarozzo MT, Giuliani N, Accardi F. Monoclonal and bispecific Anti-BCMA antibodies in multiple myeloma. J Clin Med. 2020;9(9):3022. https:\/\/doi.org\/10.3390\/jcm9093022.","journal-title":"J Clin Med"},{"issue":"6","key":"506_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg use associated with Ten-Fold reduction of serious infections in multiple myeloma patients treated with Anti-BCMA bispecific antibodies. Blood Cancer Discov. 2023;4(6):440\u201351. https:\/\/doi.org\/10.1158\/2643-3230.BCD-23-0049.","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"506_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jtct.2022.03.005","volume":"28","author":"S Josyula","year":"2022","unstructured":"Josyula S, Pont MJ, Dasgupta S, Song X, Thomas S, Pepper G, et al. Pathogen-Specific humoral immunity and infections in B cell maturation antigen-Directed chimeric antigen receptor T cell therapy recipients with multiple myeloma. Transpl Cell Ther. 2022;28(6):304. https:\/\/doi.org\/10.1016\/j.jtct.2022.03.005.","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"506_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","volume":"14","author":"K Nath","year":"2024","unstructured":"Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N, et al. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024;14(1):88. https:\/\/doi.org\/10.1038\/s41408-024-01043-5.","journal-title":"Blood Cancer J"},{"key":"506_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.blre.2019.01.001","volume":"34","author":"C Girmenia","year":"2019","unstructured":"Girmenia C, Cavo M, Offidani M, Scaglione F, Corso A, Di Raimondo F, et al. Management of infectious complications in multiple myeloma patients: expert panel consensus-based recommendations. Blood Rev. 2019;34:84\u201394. https:\/\/doi.org\/10.1016\/j.blre.2019.01.001.","journal-title":"Blood Rev"},{"issue":"Suppl 4","key":"506_CR19","doi-asserted-by":"publisher","first-page":"S306","DOI":"10.1093\/cid\/ciw043","volume":"62","author":"SA Gonzalez","year":"2016","unstructured":"Gonzalez SA, Perrillo RP. Hepatitis B virus reactivation in the setting of cancer chemotherapy and other immunosuppressive drug therapy. Clin Infect Dis. 2016;62(Suppl 4):S306\u2013313. https:\/\/doi.org\/10.1093\/cid\/ciw043.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"506_CR20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s10147-020-01655-4","volume":"25","author":"S Yazaki","year":"2020","unstructured":"Yazaki S, Yamauchi T, Higashi T. High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan. Int J Clin Oncol. 2020;25(7):1327\u201333. https:\/\/doi.org\/10.1007\/s10147-020-01655-4.","journal-title":"Int J Clin Oncol"},{"key":"506_CR21","unstructured":"Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection, version 4. https:\/\/www.jsh.or.jp\/lib\/files\/medical\/guidelines\/jsh_guidlines\/B_v4.pdf. Accessed 3 Aug 2025. (in Japanese)."},{"issue":"1","key":"506_CR22","doi-asserted-by":"publisher","first-page":"7365","DOI":"10.1038\/s41598-022-10665-3","volume":"12","author":"M Fujita","year":"2022","unstructured":"Fujita M, Kusumoto S, Ishii I, Ito A, Suzuki R, Hyo R, et al. Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma. Sci Rep. 2022;12(1):7365. https:\/\/doi.org\/10.1038\/s41598-022-10665-3.","journal-title":"Sci Rep"},{"key":"506_CR23","doi-asserted-by":"publisher","unstructured":"Rees MJ, Quach H, Jardine D, Thompson A. Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with haematological malignancies. Haematologica. 2025 Jul;31. https:\/\/doi.org\/10.3324\/haematol.2025.288359.","DOI":"10.3324\/haematol.2025.288359"},{"issue":"6","key":"506_CR24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41409-023-01960-2","volume":"58","author":"S Fu","year":"2023","unstructured":"Fu S, Zhang Q, Jing R, Zu C, Ni F, Lv Y, et al. HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy. Bone Marrow Transpl. 2023;58(6):701\u20139. https:\/\/doi.org\/10.1038\/s41409-023-01960-2.","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"506_CR25","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1007\/s00520-022-06920-y","volume":"30","author":"H Link","year":"2022","unstructured":"Link H, Kerkmann M, Holtmann L, Working Groups Supportive Care (AGSMO). Medical oncology (AIO) of the German cancer society (DKG). Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections. Support Care Cancer. 2022;30(6):5187\u2013200. https:\/\/doi.org\/10.1007\/s00520-022-06920-y.","journal-title":"Support Care Cancer"},{"issue":"3","key":"506_CR26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jvh.12305","volume":"22","author":"JP Hwang","year":"2015","unstructured":"Hwang JP, Barbo AG, Perrillo RP. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American association for the study of liver diseases. J Viral Hepat. 2015;22(3):346\u201352. https:\/\/doi.org\/10.1111\/jvh.12305.","journal-title":"J Viral Hepat"},{"issue":"6","key":"506_CR27","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","volume":"77","author":"GV Papatheodoridis","year":"2022","unstructured":"Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol. 2022;77(6):1670\u201389. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.003.","journal-title":"J Hepatol"}],"updated-by":[{"DOI":"10.1186\/s40780-025-00520-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000}}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00506-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00506-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00506-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:37:32Z","timestamp":1765802252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-025-00506-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00506-6","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s40780-025-00520-8","URL":"https:\/\/doi.org\/10.1186\/s40780-025-00520-8","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board at the Japan Community Health Care Organization (JCHO) Kyushu Hospital determined that this single-patient case report does not constitute human subjects research and waived the requirement for review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of this case report was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}